Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Wasserman

Showing results (231-240 of 299) with videos related to

Pageof 30
Sort By:
Substance Use & Misuse|December 4, 2024
Social and Environmental Predictors of Youth Alcohol and Cannabis Initiation Risk: The Moderating Role of Family History of Substance Use DisordersErin E Wood, Yuanyuan Liang, Tae-Joon Moon, et al.
Biochemical and Biophysical Research Communications|October 12, 2004
Human bronchial epithelial cells express and secrete MMP-12Mark C Lavigne, Paresh Thakker, Jason Gunn, et al.
Sexually Transmitted Diseases|August 17, 2013
Gonococcal susceptibility to cephalosporins--Hawaii, 2003 to 2011Sarah Kidd, Maria V C Lee, Eloisa Maningas, et al.
Current Biology : CB|January 27, 2015
Olfactory neuromodulation of motion vision circuitry in DrosophilaSara M Wasserman, Jacob W Aptekar, Patrick Lu, et al.
Circulation|March 3, 2017
Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension StudiesPeter P Toth, Olivier Descamps, Jacques Genest, et al.
JACC. Cardiovascular Imaging|December 19, 2021
Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, EvolocumabSatoshi Honda, Rishi Puri, Todd Anderson, et al.
The New England Journal of Medicine|November 14, 1991
Diarrheal disease during Operation Desert ShieldK C Hyams, A L Bourgeois, B R Merrell, et al.
European Heart Journal|December 19, 2018
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatmentLotte C A Stiekema, Erik S G Stroes, Simone L Verweij, et al.
Journal of Clinical Pharmacology|September 27, 2016
Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic ImpairmentJohn P Gibbs, J Greg Slatter, Ogo Egbuna, et al.
The Journal of Biological Chemistry|September 25, 2002
Identification of a novel family of cell-surface proteins expressed in human vascular endotheliumRuey-Bing Yang, Chi Kin Domingos Ng, Scott M Wasserman, et al.
Pageof 30

Showing results (231-240 of 299) with videos related to

Sort By:
Pageof 30
Substance Use & Misuse|December 4, 2024
Social and Environmental Predictors of Youth Alcohol and Cannabis Initiation Risk: The Moderating Role of Family History of Substance Use DisordersErin E Wood, Yuanyuan Liang, Tae-Joon Moon, et al.
Biochemical and Biophysical Research Communications|October 12, 2004
Human bronchial epithelial cells express and secrete MMP-12Mark C Lavigne, Paresh Thakker, Jason Gunn, et al.
Sexually Transmitted Diseases|August 17, 2013
Gonococcal susceptibility to cephalosporins--Hawaii, 2003 to 2011Sarah Kidd, Maria V C Lee, Eloisa Maningas, et al.
Current Biology : CB|January 27, 2015
Olfactory neuromodulation of motion vision circuitry in DrosophilaSara M Wasserman, Jacob W Aptekar, Patrick Lu, et al.
Circulation|March 3, 2017
Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension StudiesPeter P Toth, Olivier Descamps, Jacques Genest, et al.
JACC. Cardiovascular Imaging|December 19, 2021
Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, EvolocumabSatoshi Honda, Rishi Puri, Todd Anderson, et al.
The New England Journal of Medicine|November 14, 1991
Diarrheal disease during Operation Desert ShieldK C Hyams, A L Bourgeois, B R Merrell, et al.
European Heart Journal|December 19, 2018
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatmentLotte C A Stiekema, Erik S G Stroes, Simone L Verweij, et al.
Journal of Clinical Pharmacology|September 27, 2016
Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic ImpairmentJohn P Gibbs, J Greg Slatter, Ogo Egbuna, et al.
The Journal of Biological Chemistry|September 25, 2002
Identification of a novel family of cell-surface proteins expressed in human vascular endotheliumRuey-Bing Yang, Chi Kin Domingos Ng, Scott M Wasserman, et al.
Pageof 30